National Cancer Institute, Research Contracts Branch, PCCS, 6120 Executive Blvd, EPS/Room 635, Bethesda, MD 20892-7226

A -- PRECLINICAL EVALUATION OF INTERMEDIATE ENDPOINTS AND THEIR MODULATION BY CHEMOPREVENTIVE AGENTS SOL NCI-CN-65012-72 DUE 022096 POC Jacqueline Ballard, Contracting Officer, 301/496-8603. The National Cancer Institute is seeking contractors qualified to perform animal cancer model studies of biomarkers and intermediate endpoints that might be used in human clinical trials. This work shall be performed to assess, in detail, the biomarker modulating effects of selected chemopreventive compounds. This solicitation is an annual announcement to expand a current pool of Master Agreement (MA) Holders qualified to perform this type of work. Individual work requirements will be defined, as the need arises, by Master Agreement Orders (MAOs) issued during the period of performance, and the MAOs will be awarded based upon competition between members of that MA pool. The solicitation will be released on or about February 20, 1996, with proposals due April 5, 1996. Copies of the RFP may be obtained by contacting Ms. Desiree Sylver-Foust, Procurement Technician, PCCS, RCB, OD, NCI, Executive Plaza South, Room 635, 9000 Rockville Pike MSC 7226, Bethesda, Maryland 20892. No collect calls will be accepted. (0038)

Loren Data Corp. http://www.ld.com (SYN# 0011 19960208\A-0011.SOL)